State Legislatures Magazine 3 Strategies State Lawmakers Can Use To Check Executive Powers Magazine2021Although not many studies exist, according to one study of average earners born from 1917 through 1926, the disparity in benefits with other retirees seems to average about 26%..In normal political times neither party would allow Medicare to be cut. But because of our current highly partisan times, it would require ten Republicans to join with Democrats to stop the cuts to Medicare with new legislation if reconciliation were used..Senior advocates are concerned that all of Medicare's 60 million beneficiaries will likely see their premiums for Medicare Part B, and Medigap supplements, rise significantly to cover this one new medication. Because the drug is administered in a physician's office, it would be covered under Medicare Part B, not part D plans which pay for drugs purchased from pharmacies. Medicare typically reimburses doctors 103% of the list price of drugs administered in their office. … Continued
Nourish Seven Ways To Eat Healthier This SeasonThe Senior Citizens League is relieved that Members of Congress were able to avert the Fiscal Cliff and provide a "doc fix" without enacting harsh benefit cuts. However, topics like "chaining" the Social Security COLA and increasing means testing measures within Medicare will likely resurface next month, when Congress will be required to raise the debt ceiling address the spending cuts once again. In the meantime, TSCL will continue to inform Members of Congress about the consequences of cutting Social Security and Medicare benefits, and we will post updates here in the Legislative News section of our website.."TSCL surveys indicate there is no support for benefit cuts among older voters," Johnson says. "We have learned, however, that there is widespread support to boost the amount of wages subject to the Social Security payroll tax, and to provide more adequate Social Security income," she says. "Raising the Social Security taxable maximum is a way to do both," she points out.."The FDA's action came despite a 10-0 vote in November against approval by its panel of expert advisers, who were dubious that data from two clinical trials showed the drug was effective in early Alzheimer's patients with mild cognitive impairment; three members resigned in protest from the panel last week. The surprising decision leaves doctors turning back to data from those trials, which had conflicting results: One barely met its primary endpoint, and the other did not. As if that is not confusing enough, the mental decline that is considered an early sign of Alzheimer's disease is also present in other age-related disorders, which makes it hard to discern which patients have the disease." … Continued